Silverstein Melvin J, Savalia Nirav, Khan Sadia, Ryan Jessica
Hoag Memorial Hospital Presbyterian, Newport Beach, California; Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California.
Breast J. 2015 Jan-Feb;21(1):52-9. doi: 10.1111/tbj.12356. Epub 2015 Jan 8.
Extreme oncoplasty is a breast conserving operation, using oncoplastic techniques, in a patient who, in most physicians' opinions, requires a mastectomy. These are generally large, greater than 5 cm multifocal or multicentric tumors. Many will have positive lymph nodes. Most will require radiation therapy, even if treated with mastectomy. Sixty-six consecutive patients with multifocal, multicentric, or locally advanced tumors that spanned more than 50 mm were studied (extreme cases). All patients underwent excision and oncoplastic reconstruction using a standard or split wise pattern reduction and immediate contralateral surgery for symmetry. All received postexcisional standard whole breast radiation therapy with a boost to the tumor bed. The extreme cases were compared with 245 consecutive patients with unifocal or multifocal tumors that spanned 50 mm or less (standard cases). All extreme patients were advised to have a mastectomy; all sought a breast conserving second opinion. Diagnostic evaluation included digital mammography, ultrasound, MRI, and PET-CT (if invasive). Standard cases did extremely well. No ink on tumor was achieved 96% of the time among 245 patients. The median tumor size was 21 mm (mean 23 mm). Margins equal or greater than 1 mm were achieved in 88.6% of patients. Seventeen (6.9%) standard patients underwent re-excision to achieve wider margins and only one patient (0.4%) was converted to mastectomy. With 24 months of median follow-up, three patients (1.2%) experienced local recurrence. For extreme cases, no ink on tumor was achieved 83.3% of the time, which is comparable to published positive margin rates after standard lumpectomy. The median tumor size was 62 mm (mean 77 mm). Margins equal or greater than 1 mm were achieved in 54.5% of patients. Six (9.1%) extreme patients underwent re-excision to achieve wider margins and four patients (6.1%) were converted to mastectomy. With a follow-up of 24 months, one patient (1.5%) experienced a local recurrence. Extreme oncoplasty is a promising new concept. It allows successful breast conservation in selected patients with greater than 5 cm multifocal/multicentric tumors. It may be useful in patients with locally advanced tumors following neo-adjuvant chemotherapy. From a quality of life point of view, it is a better option than the combination of mastectomy, reconstruction, and radiation therapy. Long-term data on recurrence and survival are not available, using this approach. Based on historical data, it is expected the local recurrence will be somewhat higher but that there will be little or no impact on survival.
极限肿瘤整形手术是一种保乳手术,采用肿瘤整形技术,针对大多数医生认为需要进行乳房切除术的患者。这些患者的肿瘤通常较大,多灶性或多中心性肿瘤直径大于5厘米。许多患者会有阳性淋巴结。大多数患者即使接受乳房切除术也需要放疗。对连续66例多灶性、多中心性或局部晚期肿瘤直径超过50毫米的患者(极限病例)进行了研究。所有患者均接受切除及肿瘤整形重建,采用标准或分块式缩小整形模式,并同期进行对侧手术以保持对称。所有患者术后均接受标准的全乳放疗,并对瘤床进行加量照射。将极限病例与245例连续的单灶性或多灶性肿瘤直径50毫米及以下的患者(标准病例)进行比较。所有极限病例患者最初均被建议行乳房切除术;但他们均寻求保乳的第二种意见。诊断评估包括数字乳腺摄影、超声、MRI和PET-CT(如果是浸润性癌)。标准病例的治疗效果非常好。在245例患者中,96%的病例切缘无肿瘤染色。肿瘤中位大小为21毫米(平均23毫米)。88.6%的患者切缘达到或大于1毫米。17例(6.9%)标准病例患者接受再次切除以获得更宽切缘,仅1例患者(0.4%)转为乳房切除术。中位随访24个月时,3例患者(1.2%)出现局部复发。对于极限病例,83.3%的病例切缘无肿瘤染色,这与标准肿块切除术后公布的阳性切缘率相当。肿瘤中位大小为62毫米(平均77毫米)。54.5%的患者切缘达到或大于1毫米。6例(9.1%)极限病例患者接受再次切除以获得更宽切缘,4例患者(6.1%)转为乳房切除术。随访24个月时,1例患者(1.5%)出现局部复发。极限肿瘤整形手术是一个很有前景的新概念。它能使部分肿瘤直径大于5厘米的多灶性/多中心性肿瘤患者成功保乳。对于新辅助化疗后局部晚期肿瘤患者可能也有用。从生活质量的角度来看,它比乳房切除、重建和放疗联合应用是更好的选择。目前尚无采用这种方法的复发和生存的长期数据。根据历史数据,预计局部复发率会略高,但对生存率几乎没有影响。